Genmab A/S Annual Report

March 23, 2010 05:54 ET | Source: Genmab A/S Genmab A/S

Please see the attached pdf.
Stock exchange release number 8/2010.

Attachments

genmab_uk_web.pdf

genmab_uk_web.pdf...

Recommended Reading

July 06, 2026 13:59 ET | Source: Genmab A/S

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
Read More

$Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma$
June 29, 2026 16:14 ET | Source: Genmab A/S

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Company Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful...
Read More

$Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival$